{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:43:15Z","timestamp":1760236995525,"version":"build-2065373602"},"reference-count":60,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["CA120102"],"award-info":[{"award-number":["CA120102"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Pancreatic cancer, hepatocellular carcinoma (HCC), and mesothelioma are treatment-refractory cancers, and patients afflicted with these cancers generally have a very poor prognosis. The genomics of these tumors were analyzed as part of The Cancer Genome Atlas (TCGA) project. However, these analyses are an overview and may miss pathway interactions that could be exploited for therapeutic targeting. In this study, the TCGA Pan-Cancer datasets were queried via cBioPortal for correlations among mRNA expression of key genes in the cell cycle and mitochondrial (mt) antioxidant defense pathways. Here we describe these correlations. The results support further evaluation to develop combination treatment strategies that target these two critical pathways in pancreatic cancer, hepatocellular carcinoma, and mesothelioma.<\/jats:p>","DOI":"10.3390\/ph13020026","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T02:59:18Z","timestamp":1580957958000},"page":"26","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cyclin-Dependent Kinase and Antioxidant Gene Expression in Cancers with Poor Therapeutic Response"],"prefix":"10.3390","volume":"13","author":[{"given":"George S.","family":"Scaria","sequence":"first","affiliation":[{"name":"Research Service, Minneapolis VA Health Care System, Minneapolis, MN 55417, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betsy T.","family":"Kren","sequence":"additional","affiliation":[{"name":"Research Service, Minneapolis VA Health Care System, Minneapolis, MN 55417, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-6879","authenticated-orcid":false,"given":"Mark A.","family":"Klein","sequence":"additional","affiliation":[{"name":"Research Service, Minneapolis VA Health Care System, Minneapolis, MN 55417, USA"},{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Hematology\/Oncology Section, Primary Care Service Line, Minneapolis VA Health Care System, Minneapolis, MN 55417, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1056\/NEJMc1107627","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"365","author":"Vaccaro","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"574","DOI":"10.21037\/tlcr.2018.04.10","article-title":"Current chemotherapy strategies in malignant pleural mesothelioma","volume":"7","author":"Baas","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jjco\/hyx180","article-title":"Chemotherapy for hepatocellular carcinoma: Current status and future perspectives","volume":"48","author":"Ikeda","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.lpm.2019.02.025","article-title":"Chemotherapy for pancreatic cancer","volume":"48","author":"Springfeld","year":"2019","journal-title":"Presse Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.bjc.6602229","article-title":"Clinical anticancer drug development: Targeting the cyclin-dependent kinases","volume":"92","author":"Benson","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1038\/sj.onc.1201870","article-title":"Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression","volume":"16","author":"Frizelle","year":"1998","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jcp.21791","article-title":"Nuclear cyclin D1: An oncogenic driver in human cancer","volume":"220","author":"Kim","year":"2009","journal-title":"J. Cell. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1038\/onc.2013.137","article-title":"Signaling through cyclin D-dependent kinases","volume":"33","author":"Choi","year":"2014","journal-title":"Oncogene"},{"key":"ref_16","first-page":"123","article-title":"Palbociclib: An evidence-based review of its potential in the treatment of breast cancer","volume":"6","author":"Cadoo","year":"2014","journal-title":"Breast Cancer"},{"key":"ref_17","first-page":"232","article-title":"The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma","volume":"1845","author":"Locatelli","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/neuonc\/nos114","article-title":"p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells","volume":"14","author":"Cen","year":"2012","journal-title":"Neuro Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"20532","DOI":"10.1073\/pnas.1110085108","article-title":"Vertebrate-specific glutaredoxin is essential for brain development","volume":"108","author":"Brautigam","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1128\/MCB.23.3.916-922.2003","article-title":"The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice","volume":"23","author":"Nonn","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.freeradbiomed.2007.11.018","article-title":"Thioredoxin 2 haploinsufficiency in mice results in impaired mitochondrial function and increased oxidative stress","volume":"44","author":"Perez","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/toxsci\/kfj175","article-title":"Mitochondrial thioredoxin-2 has a key role in determining tumor necrosis factor-alpha-induced reactive oxygen species generation, NF-kappaB activation, and apoptosis","volume":"91","author":"Hansen","year":"2006","journal-title":"Toxicol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1126\/science.1158265","article-title":"Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins","volume":"320","author":"Benhar","year":"2008","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/emboj\/21.7.1695","article-title":"Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis","volume":"21","author":"Tanaka","year":"2002","journal-title":"EMBO J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"33249","DOI":"10.1074\/jbc.M203036200","article-title":"Human mitochondrial thioredoxin. Involvement in mitochondrial membrane potential and cell death","volume":"277","author":"Damdimopoulos","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/10715760500135391","article-title":"Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase","volume":"39","author":"Rigobello","year":"2005","journal-title":"Free Radic. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.bcp.2008.08.021","article-title":"The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax\/Bak-dependent process that involves peroxiredoxin 3 oxidation","volume":"76","author":"Cox","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1021\/jm300428v","article-title":"Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents","volume":"55","author":"Schuh","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41698-018-0068-8","article-title":"Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology","volume":"2","author":"Okrah","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.trecan.2016.10.009","article-title":"Eradicating Quiescent Tumor Cells by Targeting Mitochondrial Bioenergetics","volume":"2","author":"Zhang","year":"2016","journal-title":"Trends Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1038\/ncomms4295","article-title":"Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments","volume":"5","author":"Zhang","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/gutjnl-2016-312268","article-title":"Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma","volume":"66","author":"Bollard","year":"2016","journal-title":"Gut"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.celrep.2015.12.094","article-title":"Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4\/6 Inhibition Elicits Unique Vulnerabilities","volume":"14","author":"Franco","year":"2016","journal-title":"Cell Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neo.2017.05.003","article-title":"Combined Inhibition of CDK4\/6 and PI3K\/AKT\/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells","volume":"19","author":"Bonelli","year":"2017","journal-title":"Neoplasia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.18632\/oncotarget.1658","article-title":"Anti-oxidative stress response genes: Bioinformatic analysis of their expression and relevance in multiple cancers","volume":"4","author":"Rotblat","year":"2013","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5483\/BMBRep.2015.48.10.179","article-title":"Mitochondrial metabolism in cancer stem cells: A therapeutic target for colon cancer","volume":"48","author":"Song","year":"2015","journal-title":"BMB Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ccr.2011.10.001","article-title":"A systematic screen for CDK4\/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells","volume":"20","author":"Anders","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","article-title":"Auranofin: Repurposing an old drug for a golden new age","volume":"15","author":"Roder","year":"2015","journal-title":"Drugs R D"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4939-3578-9_6","article-title":"A Practical Guide to The Cancer Genome Atlas (TCGA)","volume":"1418","author":"Wang","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_40","unstructured":"The Cancer Genome Atlas Research Network (2017). Electronic address aadhe, Cancer Genome Atlas Research, N. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell, 32, 185\u2013203."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2017). Electronic address wbe, Cancer Genome Atlas Research, N. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 169, 1327\u20131341.","DOI":"10.1038\/nature20805"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., and Larsson, E. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal, 6.","DOI":"10.1126\/scisignal.2004088"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/0008-5472.CAN-15-0751","article-title":"Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma","volume":"76","author":"Archer","year":"2016","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Pelosi, E., Castelli, G., and Testa, U. (2017). Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Biomedicines, 5.","DOI":"10.3390\/biomedicines5040065"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8788","DOI":"10.1073\/pnas.1003428107","article-title":"Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity","volume":"107","author":"Weinberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature15726","article-title":"Oxidative stress inhibits distant metastasis by human melanoma cells","volume":"527","author":"Piskounova","year":"2015","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.tcb.2013.08.003","article-title":"Mitochondria: Gatekeepers of response to chemotherapy","volume":"23","author":"Sarosiek","year":"2013","journal-title":"Trends Cell Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1073\/pnas.0700690104","article-title":"Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production","volume":"104","author":"Funes","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"12486","DOI":"10.1073\/pnas.1402012111","article-title":"Tumorigenicity of hypoxic respiring cancer cells revealed by a hypoxia-cell cycle dual reporter","volume":"111","author":"Le","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1089\/ars.2011.4367","article-title":"The tumor microenvironment: Characterization, redox considerations, and novel approaches for reactive oxygen species-targeted gene therapy","volume":"19","author":"Policastro","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.biocel.2010.05.003","article-title":"Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells","volume":"43","author":"Smolkova","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1631\/jzus.B1500158","article-title":"PGC-1alpha regulates the cell cycle through ATP and ROS in CH1 cells","volume":"17","author":"Fu","year":"2016","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1083\/jcb.200912024","article-title":"Metabolic control of G1-S transition: Cyclin E degradation by p53-induced activation of the ubiquitin-proteasome system","volume":"188","author":"Mandal","year":"2010","journal-title":"J. Cell Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.freeradbiomed.2014.12.026","article-title":"CDK4-mediated MnSOD activation and mitochondrial homeostasis in radioadaptive protection","volume":"81","author":"Jin","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2014.10.001","article-title":"Is reliance on mitochondrial respiration a \u201cchink in the armor\u201d of therapy-resistant cancer?","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1089\/ars.2013.5303","article-title":"Manganese superoxide dismutase regulates a redox cycle within the cell cycle","volume":"20","author":"Sarsour","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.59.090506.155819","article-title":"The FDA critical path initiative and its influence on new drug development","volume":"59","author":"Woodcock","year":"2008","journal-title":"Annu. Rev. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1158\/1535-7163.MCT-12-0968","article-title":"Drug repurposing for gastrointestinal stromal tumor","volume":"12","author":"Pessetto","year":"2013","journal-title":"Mol. Cancer Ther."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/2\/26\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:54:50Z","timestamp":1760172890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/2\/26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["ph13020026"],"URL":"https:\/\/doi.org\/10.3390\/ph13020026","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2020,2,5]]}}}